Drug Discovery Informatics for Big Pharma: Key Webinar Insights
Collaborative Drug
MARCH 21, 2025
The pharmaceutical R&D landscape continues to evolve rapidly with advances in computational technologies and artificial intelligence.
Pharmaceuticals Related Topics 
Sustainability in pharmaceutical manufacturing: a CDMO’s contribution
BioPharma Drive: Drug Pricing
APRIL 29, 2024
Consideration of sustainability early in process development, throughout the entire development cycle, and across the entire supply chain must also become common practice.
Pharmaceuticals 
274
274 Pharmaceuticals 274
274 Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Generative AI can enhance pharmaceutical innovation – but are you ready for it?
BioPharma Drive: Drug Pricing
SEPTEMBER 16, 2024
There’s no doubt that AI and GenAI can speed up pharmaceutical innovation. But before organizations can jump into the future, it’s crucial to understand the benefits – and the risks – of advanced technology.
Pharmaceuticals 190
190 Pharmaceuticals 190
190 
How AI will reshape pharma by 2025
Drug Target Review
DECEMBER 20, 2024
Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. Looking ahead, 2025 could represent a major turning point for the pharmaceutical sector.
Clinical Trials 128
128 
Wave sees RNA editing validation in early trial results
BioPharma Drive: Drug Pricing
OCTOBER 16, 2024
The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.
RNA 358
358 
Investors put $400M into biotech licensing obesity drugs from China
BioPharma Drive: Drug Pricing
MAY 16, 2024
The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.
Licensing 356
356 
An RNAi renaissance is creating a new generation of startups
BioPharma Drive: Drug Pricing
NOVEMBER 6, 2024
Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is building on that foundation by taking the drugmaking technology in new directions.
RNA 348
348 
A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology
BioPharma Drive: Drug Pricing
SEPTEMBER 4, 2024
But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes. Over the past 10 years, PD1-blocking medicines have transformed cancer care.
CDMO Selection: The Ultimate Checklist
Drug Patent Watch
DECEMBER 11, 2024
This growth has created a competitive landscape where pharmaceutical companies must carefully evaluate and select the right CDMO partner to ensure the success of their projects. Pharmaceutical companies should look for CDMOs with a proven track record of working with various molecules and pharmaceutical companies.
‘No tolerance for failure’: An oral history of the first CRISPR medicine
BioPharma Drive: Drug Pricing
DECEMBER 10, 2023
A new sickle cell disease therapy developed by CRISPR Therapeutics and Vertex Pharmaceuticals is now approved in the U.S. This is the story of how it came to be.
Therapies 357
357 
Real-world evidence in pharmaceutical drug development – faster, safer and more relevant?
BioPharma Drive: Drug Pricing
NOVEMBER 13, 2023
Regulatory agencies have set the framework and use cases for RWE. How can these increase the probability of success or efficiency in a pre-clinical and clinical drug development program?
Drug Development 274
274 
CRISPR therapy for sickle cell approved by FDA in gene editing milestone
BioPharma Drive: Drug Pricing
DECEMBER 8, 2023
In addition to clearing Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy, the FDA also granted an early OK to Bluebird bio’s sickle cell treatment Lyfgenia.
FDA 349
349 
A new, non-opioid pain drug is here. Getting it to patients could be agony.
BioPharma Drive: Drug Pricing
JANUARY 31, 2025
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful biotechs contend with a healthcare system that’s long favored opioids?
Pharmaceuticals 319
319 
ADHD Drug Zenzedi Recalled Over Pill Mixup
Drugs.com
JANUARY 30, 2024
30, 2024 -- The maker of a drug used to treat ADHD and narcolepsy has recalled one lot of the medication after a pill mixup was discovered.The recall notice, issued by Azurity Pharmaceuticals Inc., TUESDAY, Jan. states that one lot of Zenzedi.
Drugs 347
347 
Patent Use Codes for Pharmaceutical Products: A Comprehensive Analysis
Drug Patent Watch
APRIL 17, 2025
"Patent Use Codes: The Hidden Language of Pharmaceutical Innovation As a healthcare professional, have you ever wondered what lies behind the complex world of patent use codes? In this comprehensive analysis, we delve into the world of patent use codes and explore their significance in the pharmaceutical industry.
Sourcing the Key Starting Materials (KSMs) for pharmaceutical Active Pharmaceutical Ingredients (APIs)
Drug Patent Watch
OCTOBER 1, 2024
To find Key Starting Materials (KSMs) for pharmaceutical Active Pharmaceutical Ingredients (APIs), you can follow these steps: Remember that the availability and sourcing of KSMs can vary depending on the specific API and regulatory requirements in different countries.
Pharmaceuticals 101
101 Pharmaceuticals 101
101 
US launches probe that could set stage for pharma tariffs
BioPharma Drive: Drug Pricing
APRIL 14, 2025
importing pharmaceuticals and their starting materials. The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S.
Pharmaceuticals 261
261 Pharmaceuticals 261
261 
What if a CRISPR cure isn’t such an easy choice?
BioPharma Drive: Drug Pricing
NOVEMBER 8, 2023
A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.
Therapies 327
327 
Pharmaceutical research on mRNA and CAR T-cell therapy in cancer: Pioneering the future of oncology
BioPharma Drive: Drug Pricing
OCTOBER 21, 2024
Immunotherapy and precision medicine show promise in better fighting cancer. What else does the research tell us?
Research 261
261 
World’s first CRISPR medicine approved in UK for sickle cell, beta thalassemia
BioPharma Drive: Drug Pricing
NOVEMBER 16, 2023
Clearance of Vertex Pharmaceuticals and CRISPR Therapeutics' Casgevy in the U.K. comes ahead of expected regulatory decisions in the U.S. and Europe.
Pharmaceuticals 313
313 Pharmaceuticals 313
313 
Sanofi may have found a buyer for its consumer health business
BioPharma Drive: Drug Pricing
OCTOBER 11, 2024
The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD&R, in a deal that reportedly could be worth more than $16 billion.
Pharmaceuticals 291
291 Pharmaceuticals 291
291 
After surprise trial failure, ALS doctors brace for one less treatment option
BioPharma Drive: Drug Pricing
MARCH 12, 2024
Physicians are preparing for tough conversations with patients on Amylyx Pharmaceuticals’ drug, Relyvrio, while holding out hope it still may help some with the disease.
Doctors 313
313 
Employers foresee higher health costs next year due to rising pharmacy spend
BioPharma Drive: Drug Pricing
AUGUST 21, 2024
Pharmaceuticals like the in-demand GLP-1 drugs for obesity are expected to drive increases in healthcare spending in 2025, per a new employer survey.
Pharmacy 284
284 
Startup AIRNA emerges from stealth to bring RNA editing to a rare disease
BioPharma Drive: Drug Pricing
SEPTEMBER 19, 2023
AIRNA is one of several biotechs to debut plans for target alpha-1 antitrypsin deficiency in recent years, with competitors such as AlveoGene, Wave Life Sciences and Arrowhead Pharmaceuticals.
RNA 313
313 
Lilly weight loss drug approved by FDA
BioPharma Drive: Drug Pricing
NOVEMBER 8, 2023
The pharmaceutical company will sell the GLP-1 drug, branded as Zepbound, at a list price about 20% lower than Novo Nordisk's competing drug Wegovy.
India’s Growing Importance in Generic Drug API Manufacturing
Drug Patent Watch
DECEMBER 10, 2024
India has long been recognized as a significant player in the global pharmaceutical industry, particularly in the production of generic drugs. The country’s pharmaceutical sector has experienced substantial growth over the years, driven by both domestic and international demand for affordable and high-quality medicines.
Government 96
96 
Winning Drug Patent Disputes: Proven Strategies for Pharmaceutical Companies
Drug Patent Watch
JULY 17, 2024
The High Stakes of Pharmaceutical Patent Litigation In the fiercely competitive pharmaceutical industry, patent disputes can make or break a […] Source
Top 10 CDMO Services You Didn’t Know You Needed
Drug Patent Watch
OCTOBER 28, 2024
The pharmaceutical industry relies heavily on Contract Development and Manufacturing Organizations (CDMOs) to streamline the drug development and manufacturing process. CDMOs provide a wide range of services that cater to the diverse needs of pharmaceutical companies, from early-stage development to commercial manufacturing.
When Do Drug Patents Expire: Understanding the Lifecycle of Pharmaceutical Innovations
Drug Patent Watch
OCTOBER 1, 2024
Let’s dive into the fascinating realm of pharmaceutical intellectual property and explore when drug patents expire. Drug patents are a crucial aspect of the pharmaceutical industry. Have you ever wondered why some medications seem to cost an arm and a leg, while others are surprisingly affordable?
Pharmaceuticals 111
111 
FDA OKs Amvuttra To Treat Heart Conditions
Drugs.com
MARCH 24, 2025
The drug, called Amvuttra (vutrisiran), is made by Alnylam Pharmaceuticals and is used to. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of people.
FDA 279
279 
Pfizer wins FDA approval for its $7B colitis drug
BioPharma Drive: Drug Pricing
OCTOBER 13, 2023
Acquired with the buyout of Arena Pharmaceuticals, Velsipity enters a competitive market for ulcerative colitis pills.
FDA Approval 293
293 
Trends in Pharmaceutical Mergers and Acquisitions
DrugBank
OCTOBER 4, 2024
Deal Structuring Deal structuring in pharmaceutical M&A requires a balance of financial, legal, and strategic considerations. Intellectual Property Valuation Valuing intellectual property (IP) assets is a critical component of pharmaceutical M&A, as these assets often represent a significant portion of a company's value.
Experimental Pain Med Could Give Patients New Option to Opioids
Drugs.com
JANUARY 30, 2024
For now, the drug from Vertex Pharmaceuticals is called VX-548. TUESDAY, Jan. 30, 2024 -- The first new kind of pain medication in over two decades could be on the horizon for patients, with promising results announced Tuesday from a company trial.
Pharmaceuticals 297
297 
An AI Approach to Generate Novel Pharmaceuticals using Patent Data
Drug Patent Watch
JANUARY 16, 2024
A recent article published in the Journal of Cheminformatics addresses the challenge of confirming the patent status of newly developed compounds, particularly in the pharmaceutical industry, where generating novel structures… The post An AI Approach to Generate Novel Pharmaceuticals using Patent Data appeared first on DrugPatentWatch - Make Better (..)
Pharmaceuticals 114
114 Pharmaceuticals 114
114 
Biological Characterization of One Oxadiazole Derivative (5(4‐Hydroxyphenyl)‐2‐(N‐Phenyl Amino)‐1,3,4‐Oxadiazole): In Vitro, In Silico, and Network Pharmacological Approaches
Chemical Biology and Drug Design
JANUARY 5, 2025
5(4-Hydroxyphenyl)-2-(N-Phenyl amino)-1,3,4-Oxadiazole (Hppo) can considered as a versatile agent in designing novel pharmaceuticals. Thus, our findings can provide novel and versatile compounds for the development of multidirectional drugs in the pharmaceutical industry.
Bioinformatics 100
100 
Lilly to buy injectable drug plant in manufacturing ramp-up
BioPharma Drive: Drug Pricing
APRIL 22, 2024
The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes and obesity.
Pharmaceuticals 284
284 
Poor Trial Results May Prompt Maker to Pull ALS Drug, Relyvrio, From Market
Drugs.com
MARCH 11, 2024
In a statement issued Friday, Amylyx Pharmaceuticals said that Relyvrio failed to help patients in a. MONDAY, March 11, 2024 -- Following disappointing trial results, the maker of a controversial ALS drug may pull the medication off the market.
Marketing 289
289 
Moderna Receives $590M From HHS To Develop Bird Flu Vaccine
Drugs.com
JANUARY 21, 2025
Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu. TUESDAY, Jan. 21, 2025 -- The U.S. This funding, announced Friday by Moderna.
Vaccine 262
262 
Novo Nordisk To Pay $2 Billion for New Weight Loss Drug
Drugs.com
MARCH 25, 2025
TUESDAY, March 25, 2025 -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24. The drug, called UBT251, is being developed.
Legislative Proposals to Tackle Improper Pharmaceutical Patents in the Orange Book
Drug Patent Watch
JANUARY 22, 2024
A recent article published in Health Affairs, delves into the Federal Trade Commission’s (FTC) concerns regarding the inclusion of improper patents in the FDA’s Orange Book by pharmaceutical manufacturers.
Pharmaceuticals 114
114 Pharmaceuticals 114
114 
FDA and Novo Nordisk Alert Consumers to Counterfeit Ozempic
Drugs.com
APRIL 21, 2025
Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout for counterfeit Ozempic (semaglutide) and to refrain from using the imitation drugs.Several. MONDAY, April 21, 2025 -- The U.S.
Maker Is Pulling Controversial ALS Drug Relyvrio Off the Market
Drugs.com
APRIL 4, 2024
In a statement issued Thursday, Amylyx Pharmaceuticals said that Relyvrio. THURSDAY, April 4, 2024 (HealthDayNews) -- Following disappointing trial results, the maker of a controversial ALS drug said it is pulling the medication off the market.
Marketing 279
279 
Genentech takes up a deal to make ‘molecular glue’ drugs
BioPharma Drive: Drug Pricing
SEPTEMBER 20, 2023
Targeted protein degradation has emerged as one of the more competitive areas of pharmaceutical research in recent years as scientists develop new ways to reach difficult-to-drug targets.
AI-Driven Drug Discovery: Transforming the Landscape of Pharmaceutical Research
Drug Patent Watch
APRIL 16, 2024
The pharmaceutical industry in China is undergoing a significant transformation with the adoption of artificial intelligence (AI) technology. A recent study published in the Future Journal of Pharmaceutical Sciences evaluates… Source
Pharmaceuticals 105
105 
Let's personalize your content